Work Email Address:
mcarey@mednet.ucla.edu
Work Phone Number:
(310) 206-7859
Laboratory Address:
BSRB 357
Work Address:
BSRB 351A
CAMPUS - 173722
CA
BSRB 351A
615 Charles E. Young Drive
Los Angeles, CA 90095
Affiliations |
Professor and Vice Chair, Biological Chemistry |
Director, JCCC Gene Regulation Program Area |
Dr. Carey studies biochemical and genomic mechanisms of gene activation and silencing. In 1990, Dr. Carey established biochemical systems for studying gene regulation based on a model transcriptional activator termed GAL4-VP16. Using that system, Dr. Carey established a mechanism by which genes are controlled synergistically by upstream activators. Synergy is a key principle in gene regulation and underlies the combinatorial control of gene transcription. Throughout the 1990s, Dr. Carey's lab showed that synergy is first manifested during assembly of transcription preinitiation complexes (PICs). His lab identified assembly of a co-activator complex, termed DAMed, as the key step influenced by activators. Dr. Carey has been studying the biochemistry of transcription on chromatin templates including how Pol II traverses a nucleosome, how a protein termed p300 coordinates chromatin modification with assembly of the DAMed complex and then the PIC, and how two silencing proteins termed HP1 and PRC1 silence transcription by selectively affecting key components of the DAMed complex. Dr. Carey's recent work has focused on genomics including how enhancers interact with promoters and their localization within the 3D genome. Dr. Carey served as Director of the Jonsson Comprehensive Cancer Center Gene Regulation Program from 1999-2005 and 2011-present. Dr. Carey initiated the Cold Spring Harbor Eukaryotic Gene Expression Course with his UCLA colleague, Dr. Steven Smale, and served as course director in 1997. Drs. Carey and Smale wrote a 650-page textbook titled "Transcriptional Regulation in Eukaryotes; Concepts, Strategies and Techniques." The first edition was published by CSHL Press in 2000 and the second edition was published in 2009. Dr. Carey was a scientific cofounder of Agensys, a biotechnology company focused on prostate cancer therapy. Dr. Carey is on numerous committees at UCLA that oversee undergraduate and graduate research education.